| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong Medical Centre, Hong Kong SAR, China
Purpose: In this study, we measured the serum interleukin-8 (IL-8) levels in patients with hepatocellular carcinoma (HCC) to evaluate its correlation with clinicopathological features and prognosis.
Experimental Design: ELISA was used to detect the concentrations of IL-8, vascular endothelial growth factor, and macrophage migration inhibitory factor in preoperative sera of 59 patients with resection of HCC and 15 healthy subjects.
Results: Preoperative serum IL-8 was found to be significantly elevated in patients with HCC compared with healthy subjects (median, 17.6 versus 1.0 pg/ml, P = 0.046). The levels of IL-8 correlated significantly with a large tumor size (>5 cm), absence of tumor capsule, presence of venous invasion, and advanced pathological tumor-node-metastasis stage. Serum IL-8 level was a significant prognostic factor in terms of disease-free and overall survival. Patients with a serum IL-8 level of >17.6 pg/ml had a poorer disease-free survival than those with a level of <17.6 pg/ml (median disease-free survival 4.7 versus 19.2 months). Multivariate analyses showed that serum IL-8 level was a significant and independent prognostic factor of survival.
Conclusions: Significant correlations of serum IL-8 levels with tumor size and tumor stage suggest that IL-8 may be directly or indirectly involved in the progression of HCC. These findings indicate that serum IL-8 may be a useful biological marker of tumor invasiveness and an independent prognostic factor for patients with HCC.
This article has been cited by other articles:
|
|
 |
|
  T. K. Lee, R. T.P. Poon, A. P. Yuen, M. T. Ling, X. H. Wang, Y. C. Wong, X. Y. Guan, K. Man, Z. Y. Tang, and S. T. Fan Regulation of Angiogenesis by Id-1 through Hypoxia-Inducible Factor-1{alpha}-Mediated Vascular Endothelial Growth Factor Up-regulation in Hepatocellular Carcinoma Clin. Cancer Res., December 1, 2006; 12(23): 6910 - 6919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Ueda, Y. Basaki, M. Yoshie, K. Ogawa, S. Sakisaka, M. Kuwano, and M. Ono PTEN/Akt Signaling through Epidermal Growth Factor Receptor Is Prerequisite for Angiogenesis by Hepatocellular Carcinoma Cells That Is Susceptible to Inhibition by Gefitinib. Cancer Res., May 15, 2006; 66(10): 5346 - 5353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fan, Y. Chen, H. M. Chan, P. K. H. Tam, and Y. Ren Removing intensity effects and identifying significant genes for Affymetrix arrays in macrophage migration inhibitory factor-suppressed neuroblastoma cells PNAS, December 6, 2005; 102(49): 17751 - 17756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Trevino, J. M. Summy, M. J. Gray, M. B. Nilsson, D. P. Lesslie, C. H. Baker, and G. E. Gallick Expression and Activity of Src Regulate Interleukin-8 Expression in Pancreatic Adenocarcinoma Cells: Implications for Angiogenesis Cancer Res., August 15, 2005; 65(16): 7214 - 7222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. H. Benoy, R. Salgado, P. Van Dam, K. Geboers, E. Van Marck, S. Scharpe, P. B. Vermeulen, and L. Y. Dirix Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival Clin. Cancer Res., November 1, 2004; 10(21): 7157 - 7162. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
